Advertisement

Perioperative venous thromboembolism risk considerations in the gender diverse patient – Should we consider more than just estrogen?

Published:December 21, 2022DOI:https://doi.org/10.1016/j.thromres.2022.12.006
      A 20-year-old assigned female at birth (AFAB) transmasculine individual was evaluated to undergo gender-affirming mastectomy. He was on oral ethynodiol-ethinyl estradiol (a combination oral contraceptive), testosterone cypionate injections, oral paroxetine, and oral trazodone. The patient's preoperative body mass index (BMI) was 40 kg/m2. His preoperative Caprini score was 4. He was deemed an appropriate operative candidate and underwent gender-affirming mastectomy as an outpatient surgery. Eight days postoperatively, he presented with acute chest and back pain with dyspnea. He was found to have bilateral pulmonary emboli on computed tomography angiography (CTA). The patient later recalled that other family members experienced prior thrombotic events; therefore, the patient's true preoperative Caprini score was 7. His thrombophilia workup was negative. The patient received a 6-month course of anticoagulation. Additionally, cessation of the oral contraceptive and alternative menstrual suppression management and contraceptive options were discussed with the patient. He ultimately chose to have an etonogestrel implant placed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tadesse T.A.
        • Kedir H.M.
        • Fentie A.M.
        • Abiye A.A.
        Venous thromboembolism risk and thromboprophylaxis assessment in surgical patients based on Caprini risk assessment model.
        Risk Manag. Healthc. Policy. 2020; 13: 2545-2552https://doi.org/10.2147/RMHP.S272852
        • Rochlin D.H.
        • Morrison S.D.
        • Kuzon W.M.
        A call for consideration of gender identity in venous thromboembolism risk assessment.
        Ann. Surg. 2021; 274: e191-e192https://doi.org/10.1097/SLA.0000000000004654
        • Goldstein Z.
        • Khan M.
        • Reisman T.
        • Safer J.D.
        Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy.
        J. Blood Med. 2019; 10: 209-216https://doi.org/10.2147/JBM.S166780
        • Kotamarti V.S.
        • Greige N.
        • Heiman A.J.
        • Patel A.
        • Ricci J.A.
        Risk for venous thromboembolism in transgender patients undergoing cross-sex hormone treatment: a systematic review.
        J. Sex. Med. 2021; 18: 1280-1291https://doi.org/10.1016/j.jsxm.2021.04.006
        • Pannucci C.J.
        • Barta R.J.
        • Portschy P.R.
        • et al.
        Assessment of postoperative venous thromboembolism risk in plastic surgery patients using the 2005 and 2010 Caprini Risk score.
        Plast. Reconstr. Surg. 2012; 130: 343-353https://doi.org/10.1097/PRS.0b013e3182589e49
        • Houghton D.E.
        • Alsawas M.
        • Barrioneuvo P.
        • et al.
        Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis.
        Thromb. Res. 2018; 172: 94-103https://doi.org/10.1016/j.thromres.2018.10.023
        • Scheres L.J.J.
        • Selier N.L.D.
        • Nota N.M.
        • van Diemen J.J.K.
        • Cannegieter S.C.
        • den Heijer M.
        Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen.
        J. Thromb. Haemost. 2021; 19: 1029-1037https://doi.org/10.1111/jth.15256
        • Getahun D.
        • Nash R.
        • Flanders W.D.
        • et al.
        Cross-sex hormones and acute cardiovascular events in transgender persons.
        Ann. Intern. Med. 2018; 169: 205-213https://doi.org/10.7326/M17-2785
        • Boskey E.R.
        • Taghinia A.H.
        • Ganor O.
        Association of surgical risk with exogenous hormone use in transgender patients: a systematic review.
        JAMA Surg. 2019; 154: 159-169https://doi.org/10.1001/jamasurg.2018.4598
        • Berry M.G.
        • Curtis R.
        • Davies D.
        Female-to-male transgender chest reconstruction: a large consecutive, single-surgeon experience.
        J. Plast. Reconstr. Aesthet. Surg. 2012; 65: 711-719https://doi.org/10.1016/j.bjps.2011.11.053
      1. . IK Berrahou A Grimes AM Autry M. Hawkins Management of Menstruation in Transgender and Gender Nonbinary Adolescents. Clinical Obstetrics and Gynecology.:10.1097/GRF.0000000000000710. doi:10.1097/GRF.0000000000000710.

        • Gomes M.P.V.
        • Deitcher S.R.
        Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.
        Arch. Intern. Med. 2004; 164: 1965-1976https://doi.org/10.1001/archinte.164.18.1965
        • Valente D.S.
        • Carvalho L.A.
        • Zanella R.K.
        • Valente S.
        Venous thromboembolism following elective aesthetic plastic surgery: a longitudinal prospective study in 1254 patients.
        Plast. Surg. Int. 2014; 2014565793https://doi.org/10.1155/2014/565793
        • Glisic M.
        • Shahzad S.
        • Tsoli S.
        • et al.
        Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis.
        Eur. J. Prev. Cardiol. 2018; 25: 1042-1052https://doi.org/10.1177/2047487318774847
        • Tepper N.K.
        • Whiteman M.K.
        • Marchbanks P.A.
        • James A.H.
        • Curtis K.M.
        Progestin-only contraception and thromboembolism: a systematic review.
        Contraception. 2016; 94: 678-700https://doi.org/10.1016/j.contraception.2016.04.014
        • Glueck C.J.
        • Goldenberg N.
        • Wang P.
        Testosterone therapy, thrombophilia, venous thromboembolism, and thrombotic events.
        J. Clin. Med. 2018; 8: E11https://doi.org/10.3390/jcm8010011
        • Le Moigne E.
        • Tromeur C.
        • Delluc A.
        • et al.
        Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study.
        Haematologica. 2016; 101: e12-e14https://doi.org/10.3324/haematol.2015.134882
        • Klok F.A.
        • Barco S.
        Optimal management of hormonal contraceptives after an episode of venous thromboembolism.
        Thromb. Res. 2019; 181: S1-S5https://doi.org/10.1016/S0049-3848(19)30357-3
        • Haveles C.S.
        • Wang M.M.
        • Arjun A.
        • Zaila K.E.
        • Lee J.C.
        Effect of cross-sex hormone therapy on venous thromboembolism risk in male-to-female gender-affirming surgery.
        Ann. Plast. Surg. 2021; 86: 109-114https://doi.org/10.1097/SAP.0000000000002300